A booster dose of a COVID-19 vaccine is now recommended for some at-risk groups. A booster should also be considered for adults and children over 5 with risk factors.
The Australian Technical Advisory Group on Immunisation (ATAGI) recommends a 2023 COVID-19 vaccine booster dose for adults in the following groups if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, and regardless of the number of prior doses received:
- All adults aged 65 years and over
- Adults (18-64 years) with medical comorbidities that increase their risk of severe COVID-19 or disability with significant or complex health needs.
ATAGI advises the following groups to consider a 2023 booster dose if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, regardless of the number of prior doses received, based on an individual risk-benefit assessment with their immunisation provider.
- All Adults aged 18-64 years without risk factors for severe COVID-19
- Children and adolescents aged 5-17 years with medical comorbidities that increase their risk of severe COVID-19 or disability with significant or complex health needs.
ATAGI advises that a booster dose is not recommended at this time for children and adolescents aged under the age of 18 who do not have any risk factors for severe COVID-19.
Regarding vaccine choice, all currently available COVID-19 vaccines are anticipated to provide benefits as a booster dose; however, bivalent mRNA booster vaccines are preferred over other vaccines. These include: Pfizer Original/Omicron BA.4/5, Pfizer Original/Omicron BA.1 or Moderna Original/Omicron BA.1. Moderna Original/Omicron BA.4/5 is currently under evaluation by the Therapeutic Goods Administration.
COVID-19 vaccine can be co-administered with influenza and other vaccines.
Administration of a 2023 COVID-19 booster dose should aim to occur prior to June 2023 and at a time of 6 months or greater following the most recent COVID-19 vaccine dose or confirmed infection.
Ongoing surveillance of COVID-19 infection rates and clinical outcomes, new variants, and vaccine effectiveness will inform future recommendations for additional booster doses.
Age |
At risk** |
No risk factors |
---|---|---|
<5 years |
Not recommended |
Not recommended |
5-17 years |
Consider |
Not recommended |
18-64 years |
Recommended |
Consider |
≥ 65 years |
Recommended |
Recommended |
|
More information
ATAGI statement on 2023 Boosters for COVID-19
ATAGI recommended COVID-19 doses and vaccines
ATAGI recommends the COVID-19 vaccination for some children aged 6 months to under 5 years.
ATAGI statement on the use of the Moderna bivalent Original/Omicron vaccine
Australian Department of Health - Information for people with disability on COVID-19 vaccines